Market LIVE
Published markets; coverage varies by country
Product profile · United States

ONIVYDE

 ·  Patent Litigation & Settlement History ↓

IngredientIRINOTECAN HYDROCHLORIDE
Application typeNDA
Application207793
Product001
Dosage formINJECTABLE, LIPOSOMAL
RouteINTRAVENOUS
StrengthEQ 43MG BASE/10ML (EQ 4.3MG BASE/ML)
Approval date2015-10-22
Marketing statusPrescription
Status event—
ApplicantIPSEN
Product source

Current GenericRadar decision

Year2022
SelectionDEEP_REVIEW
ReviewFINAL
Anchor typeREGULATORY_EXCLUSIVITY
Anchor date2022-10-22
Patent anchor—
Exclusivity anchor2022-10-22
Protection date2036-10-15
First Final ANDA—
Status event—

GNR judgment: DEEP_REVIEW. Reference year: 2022. Anchor type: REGULATORY_EXCLUSIVITY. Patent anchor: not recorded. Exclusivity anchor: 2022-10-22. Anchor date: 2022-10-22. Patent tail: yes. Exclusivity tail: yes. Review status: FINAL. Historical detailed rationale is retained in the evidence snapshot; this is a structured English summary, not a literal translation.

Patent estate

PatentEffective dateOfficial listingTRUE_DSDS gradeClaim classification / basisPTEPEDFamily
83292132027-01-06DS/DP —NNDP
English description not available.
———
83292132027-01-06ORANGE_BOOK —NNDP
English description not available.
———
81478672028-08-29DS/DP —NNDP
English description not available.
———
81478672028-08-29ORANGE_BOOK —NNDP
English description not available.
———
109807952033-06-12U U-1848NNU
English description not available.
———
109807952033-06-12ORANGE_BOOK U-1848NNU
English description not available.
———
113695972033-06-12U U-1848NNU
English description not available.
———
113695972033-06-12ORANGE_BOOK U-1848NNU
English description not available.
———
123646912033-06-12U U-1848NNU
English description not available.
———
123646912033-06-12ORANGE_BOOK U-1848NNU
English description not available.
———
93394972033-06-12U U-1848NNU
English description not available.
———
93394972033-06-12ORANGE_BOOK U-1848NNU
English description not available.
———
93644732033-06-12U U-1856NNU
English description not available.
———
93644732033-06-12ORANGE_BOOK U-1856NNU
English description not available.
———
94521622033-06-12U U-1899NNU
English description not available.
———
94521622033-06-12ORANGE_BOOK U-1899NNU
English description not available.
———
94924422033-06-12U U-1899NNU
English description not available.
———
94924422033-06-12U U-1917NNU
English description not available.
———
94924422033-06-12U U-1848NNU
English description not available.
———
94924422033-06-12ORANGE_BOOK U-1848;U-1899;U-1917NNU
English description not available.
———
97177242033-06-12U U-2091NNU
English description not available.
———
97177242033-06-12U U-1848NNU
English description not available.
———
97177242033-06-12ORANGE_BOOK U-1848;U-2091NNU
English description not available.
———
113445522036-08-19U U-3824NNU
English description not available.
———
113445522036-08-19ORANGE_BOOK U-3824NNU
English description not available.
———
104563602036-10-15DP —NNDP
English description not available.
———
104563602036-10-15ORANGE_BOOK —NNDP
English description not available.
———
109939142036-10-15DP —NNDP
English description not available.
———
109939142036-10-15ORANGE_BOOK —NNDP
English description not available.
———
120594972036-10-15DP —NNDP
English description not available.
———
120594972036-10-15ORANGE_BOOK —NNDP
English description not available.
———

Regulatory exclusivity

CodeStart dateEnd dateScopeEntire productAll indicationsFull coverage dateCombinationSource
NP2015-10-222018-10-22English description not available.YY2018-10-22
ODE-99
Full coverage date: 2018-10-22
Source
ODE-992015-10-222022-10-22English description not available.NN—
ODE-99
Full coverage date: —
Source
I-9322024-02-132027-02-13English description not available.NN——Source
I-9322024-02-132027-02-13English description not available.NN—
ODE-99
Full coverage date: —
Source
ODE-4632024-02-132031-02-13English description not available.NN——Source
ODE-4632024-02-132031-02-13English description not available.NN—
ODE-99
Full coverage date: —
Source

2026-10-10 · CURRENT_SOURCE_RECORDS_FOUND · Historical coverage: NOT_COMPLETE

Generic approval evidence

Application / productEventFinal dateTentative dateApplicantAuthorized genericExact mappingSource
No generic approval facts are linked to this product.

Market Entry Information

API filings, authorized generics and linked regulatory milestones.

API Master Files & Certifications 0 records

Ingredient-level registrations from linked public manufacturer portfolios. A filing does not establish supply to this finished product. DMFs are not FDA approvals.

APIHolder / manufacturerHolder countryFiling typeNumberStatusFiled dateAvailable for referenceSourceLast verified
No master-file or certification records are linked through public manufacturer portfolios.

Authorized Generics 0 records

Authorized generics are shown separately from independent ANDA approvals.

Application / productApplicantEvent / status First marketed Product mappingSourceLast verified
No authorized-generic records are linked to this product.

Tentative ANDA Approvals 0 records

Tentative approval is not final approval. Historical tentative approvals remain visible after a linked final approval.

Application / productApplicantEvent / status Tentative date Follow-up final approvalProduct mappingSourceLast verified
No tentative-approval records are linked to this product.

Paragraph IV Challenges 0 records

Paragraph IV challenges below are sourced from legal records separately from FDA approvals. An ANDA filing, lawsuit or settlement does not establish final approval or commercial launch.

Application / productApplicantEvent / status Certification event date Product mappingSourceLast verified
No structured Paragraph IV certification events are linked in the available approval evidence.

Final ANDA Approvals 0 records

Approval dates do not establish commercial launch. Product mapping is shown for each linked record.

Application / productApplicantEvent / status Final approval date Product mappingSourceLast verified
No final-approval records are linked to this product.
Decision evidence (19)
TypeDateRoleBasisSource
PATENT2027-01-06FTO_TAILEnglish description not available.Source
PATENT2028-08-29FTO_TAILEnglish description not available.Source
PATENT2033-06-12FTO_TAILEnglish description not available.Source
PATENT2033-06-12FTO_TAILEnglish description not available.Source
PATENT2033-06-12FTO_TAILEnglish description not available.Source
PATENT2033-06-12FTO_TAILEnglish description not available.Source
PATENT2033-06-12FTO_TAILEnglish description not available.Source
PATENT2033-06-12FTO_TAILEnglish description not available.Source
PATENT2033-06-12FTO_TAILEnglish description not available.Source
PATENT2033-06-12FTO_TAILEnglish description not available.Source
PATENT2036-08-19FTO_TAILEnglish description not available.Source
PATENT2036-10-15FTO_TAILEnglish description not available.Source
PATENT2036-10-15FTO_TAILEnglish description not available.Source
PATENT2036-10-15FTO_TAILEnglish description not available.Source
REGULATORY_EXCLUSIVITY—FTO_TAILEnglish description not available.Source
REGULATORY_EXCLUSIVITY—REGULATORY_SCOPE_CONTEXTEnglish description not available.Source
REGULATORY_EXCLUSIVITY—FTO_TAILEnglish description not available.Source
REGULATORY_EXCLUSIVITY—CANONICAL_ANCHOREnglish description not available.Source
REGULATORY_STATUS2022-10-22CANONICAL_DECISIONEnglish description not available.Source
Independent legal-event information

Litigation & Settlement History

Settlement launch rights generally apply only to the named parties and product scope. These records do not change GenericRadar patent/exclusivity anchors or current decisions.

No litigation or settlement record currently linked to this product.